Concurrent Investment Advisors LLC Has $548,000 Stock Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

Concurrent Investment Advisors LLC increased its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 11.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,148 shares of the financial services provider’s stock after buying an additional 436 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in iShares Biotechnology ETF were worth $548,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of IBB. Sequoia Financial Advisors LLC grew its holdings in shares of iShares Biotechnology ETF by 8.3% during the third quarter. Sequoia Financial Advisors LLC now owns 2,608 shares of the financial services provider’s stock valued at $380,000 after buying an additional 199 shares in the last quarter. NorthCrest Asset Manangement LLC grew its holdings in shares of iShares Biotechnology ETF by 12.3% during the third quarter. NorthCrest Asset Manangement LLC now owns 3,290 shares of the financial services provider’s stock valued at $479,000 after buying an additional 360 shares in the last quarter. Riggs Asset Managment Co. Inc. grew its stake in iShares Biotechnology ETF by 1,314.0% in the third quarter. Riggs Asset Managment Co. Inc. now owns 1,513 shares of the financial services provider’s stock valued at $220,000 after purchasing an additional 1,406 shares in the last quarter. Traynor Capital Management Inc. grew its stake in iShares Biotechnology ETF by 11.2% in the third quarter. Traynor Capital Management Inc. now owns 25,004 shares of the financial services provider’s stock valued at $3,641,000 after purchasing an additional 2,525 shares in the last quarter. Finally, Fidelis Capital Partners LLC grew its stake in iShares Biotechnology ETF by 8.4% in the third quarter. Fidelis Capital Partners LLC now owns 5,253 shares of the financial services provider’s stock valued at $747,000 after purchasing an additional 409 shares in the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

Shares of NASDAQ IBB opened at $138.74 on Tuesday. The business’s 50-day moving average price is $135.64 and its two-hundred day moving average price is $140.77. iShares Biotechnology ETF has a one year low of $123.60 and a one year high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The company also recently announced a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were paid a $0.0624 dividend. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.